Neurodegeneration with Brain Iron Accumulation (NBIA) comprises a group of rare, genetically heterogeneous neurodegenerative disorders characterized by abnormal iron deposition in the brain, particularly in the globus pallidus and substantia nigra. The clinical phenotype includes progressive movement disorders and cognitive decline[@kruer2022]. NBIA disorders are part of the broader category of neurodegeneratived diseases affecting the basal ganglia, and share features with Parkinson's disease and Huntington's disease.
NBIA disorders are rare, with an estimated prevalence of 1-2 per 1,000,000 individuals worldwide. However, this likely underestimates true prevalence due to underdiagnosis. PKAN (pantothenate kinase-associated neurodegeneration) is the most common subtype, accounting for approximately 35-50% of all NBIA cases[@gregory2021]. The disorders affect both males and females equally and typically present in childhood or early adolescence, though adult-onset variants exist.
Neurodegeneration with Brain Iron Accumulation (NBIA) comprises a group of rare, genetically heterogeneous neurodegenerative disorders characterized by abnormal iron deposition in the brain, particularly in the globus pallidus and substantia nigra. The clinical phenotype includes progressive movement disorders and cognitive decline[@kruer2022]. NBIA disorders are part of the broader category of neurodegeneratived diseases affecting the basal ganglia, and share features with Parkinson's disease and Huntington's disease.
NBIA disorders are rare, with an estimated prevalence of 1-2 per 1,000,000 individuals worldwide. However, this likely underestimates true prevalence due to underdiagnosis. PKAN (pantothenate kinase-associated neurodegeneration) is the most common subtype, accounting for approximately 35-50% of all NBIA cases[@gregory2021]. The disorders affect both males and females equally and typically present in childhood or early adolescence, though adult-onset variants exist.
| Subtype | Gene | Protein | Inheritance | Key Features | Frequency |
|---------|------|---------|-------------|--------------|-----------|
| PKAN | PANK2 | Pantothenate Kinase 2 | AR | Rapid progression, eye involvement, "eye of the tiger" sign | 35-50% |
| PLAN | PLA2G6 | iPLA2-VI | AR | Dystonia, cognitive decline, iron accumulation | 20-25% |
| BPAN | WDR45 | WD40 Repeat Protein | X-linked | Developmental delay, seizures, adult-onset neurodegeneration | 5-10% |
| FA2H | FA2H | Fatty Acid 2-Hydroxylase | AR | Spastic paraplegia, ataxia, cognitive decline | 3-5% |
| MPAN | COASY/MTOR | Coenzyme A Synthetase/mTOR | AR | Late onset, psychiatric symptoms | 3-5% |
| CoPAN | COASY | Coenzyme A Synthetase | AR | Corticobasal syndrome features | Rare |
| WSSPN | WDR45B | WD40 Repeat Protein | AR | Severe developmental delay | Very rare |
| PANH | PANK2 | Pantothenate Kinase | AR | Variant PKAN presentation | Rare |
PKAN is the most common and well-studied NBIA subtype, caused by mutations in the PANK2 gene[@zhou2020]. The disorder typically presents in early childhood with progressive dystonia, dysarthria, and cognitive decline. Classic PKAN shows the characteristic "eye of the tiger" sign on brain MRI, with central T2 hyperintensity surrounded by hypointensity in the globus pallidus. Early-onset cases progress rapidly, while late-onset variants may have slower progression.
PLAN results from mutations in PLA2G6[@mori2019]. Patients typically present between ages 2-4 years with progressive gait disturbance, dystonia, and neurodevelopmental regression. Brain MRI shows iron accumulation in the globus pallidus and substantia nigra, with cerebellar atrophy in later stages. PLAN has a broader phenotype than PKAN, including early-onset dystonia-parkinsonism.
BPAN is caused by de novo mutations in the X-linked WDR45 gene[@hayflick2021]. It is the most common X-linked NBIA disorder. Affected individuals typically present with early-onset seizures and developmental delay in childhood, followed by progressive neurodegeneration in adulthood. The "eye of the tiger" sign is less common in BPAN.
Mutations in FA2H[@edvardson2020] cause a spectrum of disorders including hereditary spastic paraplegia (SPG35) and NBIA. Clinical features include spastic paraplegia, ataxia, seizures, and cognitive decline. Brain MRI shows iron deposition in the globus pallidus and substantia nigra, along with white matter abnormalities.
MPAN is caused by mutations in the COASY gene[@dusi2022], which encodes Coenzyme A synthetase. It presents in adolescence or early adulthood with progressive motor symptoms including dystonia and parkinsonism. Cognitive decline and psychiatric symptoms are also common features.
Mutations in NBIA genes lead to dysfunction in iron metabolism pathways, causing pathological iron accumulation in the basal ganglia. The iron deposition triggers oxidative stress through Fenton chemistry, generating reactive oxygen species that damage neurons[@crigler2021]. Iron accumulation primarily occurs in the globus pallidus and substantia nigra pars reticulata, regions rich in iron-handling proteins.
PANK2 mutations disrupt coenzyme A (CoA) biosynthesis, leading to impaired mitochondrial function and increased oxidative stress in neurons. CoA is essential for cellular metabolism, lipid synthesis, and mitochondrial function. The disruption of CoA pathways in PKAN provides a rationale for CoA-supplementation therapeutic approaches[@campellone2023].
Iron accumulation in NBIA leads to mitochondrial dysfunction through multiple mechanisms: oxidative stress damages mitochondrial DNA and proteins, iron overload impairs electron transport chain Complex I activity, and ferritin accumulation sequesters iron in a redox-inactive form. This creates a vicious cycle of mitochondrial damage and iron accumulation.
Cognitive impairment progresses in most patients, ranging from mild executive dysfunction to severe dementia. The pattern typically involves:
Retinal degeneration and optic atrophy are common in certain NBIA subtypes, particularly PKAN. Visual symptoms may include:
Seizures occur in approximately 30-50% of NBIA patients, particularly in BPAN and FA2H subtypes. seizure types include:
Quantitative susceptibility mapping (QSM) and R2* relaxometry can track iron accumulation over time and monitor treatment response. These techniques are increasingly used in clinical trials for NBIA disorders.
Genetic testing is the gold standard for NBIA diagnosis. Targeted gene panels for NBIA disorders are available and include:
Diagnosis is based on:
NBIA must be differentiated from:
Deferoxamine and deferasirox may reduce iron burden, though efficacy varies by subtype. Chelation therapy requires careful monitoring due to potential side effects:
Pantethine (a stable derivative of pantothenate) and CoA supplementation have shown benefit in some PKAN patients[@collins2022]. This approach aims to bypass the defective PANK2 enzyme. Clinical trials are ongoing.
DBS can be effective for severe dystonia in selected patients. Target regions include:
Several clinical trials are investigating new treatments for NBIA disorders:
Prognosis varies significantly by subtype and age of onset: